ERAS - Erasca, Inc. Common Stock

Day	1m	10m	60m	PreMarket	Market	AfterHours	Gap
2.51 0.01 (0.4%)	---	---	---	-0.09 (-3.59%)	0.05 (2.06%)	0.03 (1.2%)	0.03 (1.2%)

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

Category: PHARMACEUTICAL PREPARATIONS

Market Period: AfterHours

Earnings & Ratios

Basic EPS:: -0.12
Diluted EPS:: -0.12
Basic P/E:: -21.0
Diluted P/E:: -21.0
RSI(14) 1m:: 25.0
VWAP:: 2.52
RVol:: 0.4199

Events

Period	Kind	Movement	Occurred At
1m	Price increase 1m	2.49 +0.03 (+1.01%)	Oct 15 15:41
1m	Price increase 1m	2.45 +0.03 (+1.03%)	Oct 15 09:32
1m	Price increase 1m	2.43 +0.03 (+1.25%)	Oct 15 09:31
1m	Price decrease 1m	2.39 -0.04 (-1.65%)	Oct 15 09:30
10m	Price decrease 10m	2.38 -0.09 (-3.64%)	Oct 15 09:05